• Pacira Pharmaceuticals Inc. reported total revenues for the quarter ended March 31, 2013, were $11.6 million compared with $7.8 million for the quarter ended March 31, 2012. The increase in revenues was primarily driven by $10.4 million of net product sales of Exparel (bupivacaine liposome injectable suspension) in postsurgical analgesia.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST